• Publications
  • Influence
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
This investigation confirms that paroxetine and fluxetine are potent inhibitors of CYP2D6, that fluvoxamine and fluoxettine are moderate inhibitors of CyP2C19 and that fluVoxamine is a potent inhibitor of CYp1A2 in humans in vivo. Expand
Fluvoxamine is a potent inhibitor of cytochrome P4501A2.
The present study demonstrates that fluvoxamine is a very potent inhibitor of the high-affinity O-deethylation of phenacetin, which is catalysed by cytochrome P4501A2 (CYP1A2), in microsomes from three human livers. Expand
The relationship between paroxetine and the sparteine oxidation polymorphism
It is concluded that paroxetine and sparteine metabolism cosegregates, but the interphenotype difference in metabolism was less prominent at steady state than after a single dose, presumably because of saturation of thesparteine oxygenase (CYP2D6) in subjects who were extensive metabolizers. Expand
Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms
It was shown that the citalopram elimination partially depends on the mephenytoin oxygenase, since steady-state serum concentration, half-life, and area under the serum concentration/time curve for cITALopram were significantly higher in poor metabolizers of mephenYtoin than in extensive metabolizer of me Pheny toin. Expand
The hypoalgesic effect of tramadol in relation to CYP2D6 *
It is concluded that formation of (+)‐M1 by way of CYP2D6 is important for the effect of tramadol on experimental pain. Expand
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
In a large cohort of type 2 diabetics, an enormous (80-fold) variability in trough steady-state metformin plasma concentration is confirmed and OCT1 genotype has a bearing on HbA1c during meetformin treatment. Expand
Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial
It is concluded that tramadol appears to relieve both ongoing pain symptoms and the key neuropathic pain feature allodynia in polyneuropathy. Expand
The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
This study shows that CYP2D6 catalyses the metabolism of R- and S-fluoxetine and most likely the further metabolism of S-norflu oxetine but not of R -norfluxetine. Expand
Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study.
Compared with earlier results obtained with imipramine dosed on the basis of plasma level monitoring, clomipramines on fixed doses appeared less efficacious whereas the side effect profiles were the same. Expand
CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages
This review aimed to provide distinct dose recommendations for antidepressants based on the genotypes of cytochrome P450 enzymes CYP2D6 and CYP1C19 to provide a useful complementation to clinical monitoring and therapeutic drug monitoring. Expand